FDA Releases Q7 GMP for API Guidance

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-11-02-2016
Volume 11
Issue 11

he guidance addresses the good manufacturing practice for managing quality in APIs.

On Sept. 29, 2016, FDA published the revised Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, Guidance for Industry. The guidance document address good manufacturing practices (GMPs) for a quality management system for APIs. The guidance also helps companies ensure the purported API quality and purity characteristics are met. The guidance replaces Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients and changes the International Council for Harmonization (ICH) codification from Q7A to Q7.

The revised guidance addresses all aspects of API manufacture including the principles of quality management, the responsibilities of the quality unit, production activities, internal audits, and product quality reviews. Personnel qualifications, hygiene, and the qualification of consultants are discussed. The guidance also details GMP requirements for facility design and construction and equipment used. Several other API manufacturing topics, including materials management, process controls, laboratory controls, packaging, storage and distribution, validation, and change control, are discussed.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content